Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
West China Hospital Of Sichuan University manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution shows that the hospital's current legal efforts are split between different technical specialties or examination groups. The involvement of 2 distinct art units suggests that the applications cover varied enough subject matter to require different specialized reviews.
ALLEN, MICHAEL D is the busiest examiner for the portfolio, currently overseeing 1 pending office action. Given that there are 2 pending office actions in total, the workload is split among the 2 distinct examiners involved. With 2 distinct examiners reviewing the applications, the hospital must navigate two different sets of examiner preferences and timelines simultaneously. This decentralized prosecution strategy requires a broader management approach than a portfolio concentrated under a single individual.
The data indicates that the hospital's intellectual property strategy in Biotechnology & Pharmaceuticals is active across 2 distinct art units. This variety in examination environments means that the hospital is pursuing multiple technical paths. For practitioners, the involvement of 2 distinct examiners and 2 pending office actions represents a diversified prosecution docket that requires attention to the specific standards of each assigned art unit and the 1 busiest examiner pending workload.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEN, MICHAEL D | 1 | 32.0% | +49.4% |
| BENAVIDES, JENNIFER ANN | 1 | 51.2% | +47.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17910310 | APPLICATION OF IFN-y IN PREPARING ANTI-TUMOR ADJUVANT DRUG | BENAVIDES, JENNIFER ANN | 32d overdue |
| 18017746 | EBV-TARGETED ALLOGENEIC B CELL VACCINE AND PREPARATION METHOD THEREFOR | ALLEN, MICHAEL D | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18017746 | EBV-TARGETED ALLOGENEIC B CELL VACCINE AND PREPARATION METHOD THEREFOR | ALLEN, MICHAEL D | 1672 | §103 | Non-Final OA | — | Pending | Aug 01, 2023 |
| 17910310 | APPLICATION OF IFN-y IN PREPARING ANTI-TUMOR ADJUVANT DRUG | BENAVIDES, JENNIFER ANN | 1675 | §103 | Final Rejection | 32d overdue | Pending | Mar 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial